World's First Fully Integrated LC-MS/MS Clinical Analyzer Unveiled
By LabMedica International staff writers Posted on 03 Aug 2017 |

Image: The Cascadion SM clinical lab analyzer (Photo courtesy of Thermo Fisher Scientific).
A next-generation diagnostic system brings together the convenience of clinical analyzers with the selectivity and sensitivity of liquid chromatography-tandem mass spectrometry (LC-MS/MS). The fully-automated Cascadion SM clinical analyzer system was developed by Thermo Fisher Scientific (Waltham, MA, USA) for use by non-experts in a variety of clinical settings including hospital laboratories, and to provide results for a range of frequently ordered clinical diagnostic tests.
The new Cascadion SM clinical analyzer was presented to the European market at the EuroMedLab 2017 meeting last June in Athens, Greece, and unveiled to the US clinical lab community at this year's AACC Clinical Lab Expo held in August at San Diego, CA. As a major benefit, the system can be operated by clinical laboratory staff without special training in LC-MS/MS technology.
Assays in development for the Cascadion system include those for 25OH Vitamin D, Total Testosterone, and a panel of Immunosuppressant drugs. Such diagnostic tests are projected to be launched once appropriate regulatory requirements for each country or region have been fulfilled. Development pipeline for the system includes tests for therapeutic drug monitoring, drugs of abuse, and endocrinology.
"This is a marvelous development, and it is really quite outstanding. It will fulfill the needs of many laboratories," said Prof. Brian Keevil, consultant clinical scientist and head of the Clinical Biochemistry Department, University Hospital of South Manchester NHS Foundation Trust, UK, after viewing a demonstration during EuroMedLab 2017.
James Nichols, PhD, medical director, Chemistry and Point of Care Testing, Vanderbilt University Medical Center, added, "For much of what we do in terms of chromatography and mass spectrometry, we need very highly skilled and experienced medical technologists. The Cascadion analyzer is relatively maintenance-free and because it includes specially designed reagent kits, there is not a lot of interaction required with the technology."
The Cascadion SM clinical analyzer system combines assays, software, accessories, consumables, support, and service in a stand-alone system designed to meet the regulatory requirements for routine and specialized clinical testing. The fully-automated sample-in and result-out system incorporates advanced development features including: gold standard mass spectrometry technology, complete assay kits for standardized results, traceability of results to reagent lots, automated sample preparation, LIS connectivity to maximize productivity, a turnkey solution from one supplier for easy implementation, and random access workflow for fast turnaround times.
The Cascadion system was designed and built using Thermo Fisher products and technologies combined with its industry-leading expertise in mass spectrometry. Tandem mass spectrometry, also known as MS/MS or MS2, involves multiple steps of mass spectrometry selection, with some form of fragmentation occurring in between the stages. In a tandem mass spectrometer, ions are formed in the ion source and separated by mass-to-charge ratio in the first stage of mass spectrometry (MS1). Ions of a particular mass-to-charge ratio (precursor ions) are selected and fragment ions (product ions) are created by collision-induced dissociation, ion-molecule reaction, photodissociation, or other process. The resulting ions are then separated and detected in a second stage of mass spectrometry (MS2).
After previewing the Cascadion analyzer, Michael Vogeser, senior physician and professor of laboratory medicine, University Hospital of Munich, stated "About 70% of all physician's decisions are based on laboratory tests, so the impact on laboratory testing is huge and this completely new technological approach is of enormous value to mankind."
While the instrument is still in final stages of development and not yet available for sale, CE marking and US FDA 510(k) clearance are currently being applied for by Thermo Fisher Scientific.
The new Cascadion SM clinical analyzer was presented to the European market at the EuroMedLab 2017 meeting last June in Athens, Greece, and unveiled to the US clinical lab community at this year's AACC Clinical Lab Expo held in August at San Diego, CA. As a major benefit, the system can be operated by clinical laboratory staff without special training in LC-MS/MS technology.
Assays in development for the Cascadion system include those for 25OH Vitamin D, Total Testosterone, and a panel of Immunosuppressant drugs. Such diagnostic tests are projected to be launched once appropriate regulatory requirements for each country or region have been fulfilled. Development pipeline for the system includes tests for therapeutic drug monitoring, drugs of abuse, and endocrinology.
"This is a marvelous development, and it is really quite outstanding. It will fulfill the needs of many laboratories," said Prof. Brian Keevil, consultant clinical scientist and head of the Clinical Biochemistry Department, University Hospital of South Manchester NHS Foundation Trust, UK, after viewing a demonstration during EuroMedLab 2017.
James Nichols, PhD, medical director, Chemistry and Point of Care Testing, Vanderbilt University Medical Center, added, "For much of what we do in terms of chromatography and mass spectrometry, we need very highly skilled and experienced medical technologists. The Cascadion analyzer is relatively maintenance-free and because it includes specially designed reagent kits, there is not a lot of interaction required with the technology."
The Cascadion SM clinical analyzer system combines assays, software, accessories, consumables, support, and service in a stand-alone system designed to meet the regulatory requirements for routine and specialized clinical testing. The fully-automated sample-in and result-out system incorporates advanced development features including: gold standard mass spectrometry technology, complete assay kits for standardized results, traceability of results to reagent lots, automated sample preparation, LIS connectivity to maximize productivity, a turnkey solution from one supplier for easy implementation, and random access workflow for fast turnaround times.
The Cascadion system was designed and built using Thermo Fisher products and technologies combined with its industry-leading expertise in mass spectrometry. Tandem mass spectrometry, also known as MS/MS or MS2, involves multiple steps of mass spectrometry selection, with some form of fragmentation occurring in between the stages. In a tandem mass spectrometer, ions are formed in the ion source and separated by mass-to-charge ratio in the first stage of mass spectrometry (MS1). Ions of a particular mass-to-charge ratio (precursor ions) are selected and fragment ions (product ions) are created by collision-induced dissociation, ion-molecule reaction, photodissociation, or other process. The resulting ions are then separated and detected in a second stage of mass spectrometry (MS2).
After previewing the Cascadion analyzer, Michael Vogeser, senior physician and professor of laboratory medicine, University Hospital of Munich, stated "About 70% of all physician's decisions are based on laboratory tests, so the impact on laboratory testing is huge and this completely new technological approach is of enormous value to mankind."
While the instrument is still in final stages of development and not yet available for sale, CE marking and US FDA 510(k) clearance are currently being applied for by Thermo Fisher Scientific.
Latest AACC 2017 News
- Siemens Healthineers Showcases Atellica Solution at AACC 2017
- Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo
- Combating Infectious Diseases Key Focus of AACC
- Clinical Chemistry Analyzer Provides DAU Screening
- Diatron Displays New Hematology Analyzer at UAE Congress
- Microscan Demonstrates Advanced Technology at Scientific Meeting
- AACC Middle East to Be Held in Abu Dhabi
- AACC 2017 Focus on CRISPR and Futuristic Testing Devices
- Opioid Drug Abuse Testing Key Topic at Congress
- Keynote Address to Focus on CRISPR/Cas9 Gene Editing
- Winner of Qualcomm Tricorder XPrize Unveiled at AACC
- Annual Meeting Offers Industry Education and Entertainment
Channels
Clinical Chemistry
view channel
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
Accurately monitoring drug levels in the blood is essential for effective treatment, particularly in the management of cardiovascular diseases. Traditional techniques for monitoring blood drug levels often... Read more
Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
Timely and accurate monitoring of renal function is essential for managing patients at risk of acute kidney injury (AKI), which affects about 12% of hospitalized patients and up to 57% of ICU patients.... Read more
Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
Nanopores are tiny openings that can detect individual molecules as they pass through, making them ideal for analyzing biomolecules like DNA and proteins. However, detecting proteins at extremely low ... Read moreMolecular Diagnostics
view channel
Innovative Bio-Detection Platform Improves Early Cancer Screening and Monitoring
Cancer remains one of the leading causes of death globally, underscoring the critical need for more advanced, efficient, and early detection methods. Circulating tumor cells (CTCs) are cells that have... Read more
Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer
Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer... Read more
CSF Test Distinguishes Prion Disease from Other Causes of Rapidly Progressive Dementia
Rapidly progressive dementias are a category of dementia where patients experience a swift decline from the onset of symptoms to losing functional independence, typically within two years.... Read more
Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries
Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read moreHematology
view channel
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
WBC Count Could Predict Severity of COVID-19 Symptoms
The global health crisis caused by the SARS-CoV-2 virus continues to impact millions of people worldwide, with many experiencing persistent symptoms months after the initial diagnosis. Cognitive impairment... Read more
New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
Accurate platelet count testing is a significant challenge for laboratories. Inaccurate results can lead to misdiagnosis, missed diagnoses, and delayed treatment for a variety of potentially fatal conditions,... Read more
Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
Heparin-induced thrombocytopenia (HIT), a serious side effect of the blood thinner heparin, is difficult to diagnose because thrombocytopenia, or low platelet count, can be caused by a variety of factors... Read moreImmunology
view channelCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Rapid PCR Testing in ICU Improves Antibiotic Stewardship
A collaborative study led by the University of Plymouth (Devon, UK) has shown that rapid polymerase chain reaction (PCR) testing in the intensive care unit (ICU) improved antibiotic stewardship compared... Read morePathology
view channel
Informatics Solution Elevates Laboratory Efficiency and Patient Care
QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis
Tissue analysis typically involves a pathologist reviewing scanned digital slides from a patient’s intestinal sample and marking specific areas, such as those where cancerous and related tissues are present.... Read moreTechnology
view channel
POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
Cardiovascular diseases continue to be the leading cause of death worldwide, accounting for over 19 million fatalities annually. Early detection of myocardial infarction (MI), commonly known as a heart... Read more
Study Explores Impact of POC Testing on Future of Diagnostics
In today’s rapidly changing world, having quick and accurate access to medical information is more crucial than ever. Point-of-Care Diagnostics (PoC-D) and Point-of-Care Testing (PoC-T) are making this... Read more
Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
Cancer biomarkers are valuable tools for early diagnosis as their concentration in body fluids, such as serum, can be measured to detect the disease at an earlier stage. Additionally, serum levels of these... Read moreIndustry
view channel
CACLP 2025 Unites Global Innovators in IVD Industry
CACLP (Shanghai, China) will be holding the 22nd China International In Vitro Diagnostic Expo, the largest and most influential gathering of the IVD industry in China, 22-24 March 2025 at the Hangzhou... Read more
Bio-Rad to Acquire Digital PCR Developer Stilla Technologies
Bio-Rad Laboratories (Hercules, CA, USA) has entered into a binding offer to purchase all equity interests in Stilla Technologies (Villejuif, France). The acquisition remains subject to consultation with... Read more